Fed Slashes Rate Cut Outlook and Sends Gold Crashing 10% From $5,000 — Where Is the Floor?March 19, 2026
ACCESS Newswire Non-GAAP EPS of $0.17 beats by $0.01, revenue of $5.79M misses by $0.05MMarch 19, 2026
Share Facebook Twitter LinkedIn Pinterest Email Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication
ACCESS Newswire Non-GAAP EPS of $0.17 beats by $0.01, revenue of $5.79M misses by $0.05MMarch 19, 2026